SINGAPORE, Aug 07, 2024 – NovogeneAIT Genomics is proud to announce our appointment as the sequencing service provider for sequencing of 10,000 genomes using Oxford Nanopore technology under Singapore’s National Precision Medicine (NPM) Program. This project is part of the second phase of the NPM program, which aims to create Asia’s most comprehensive consented population study to further the population’s health and well-being.

Oxford Nanopore Technologies’ PromethIon 48 device will be utilized to sequence 10,000 genomes from Singapore’s diverse population, including Malay, Indian, and Chinese communities. This initiative, which began in mid-2024 and is anticipated to continue for approximately 12 months, aims to develop a comprehensive catalog of structural variant for the country’s three major ethnic groups.

NovogeneAIT Sequencing Lab

NovogeneAIT Genomics has a strong track record in supporting Singapore’s precision medicine initiatives. We have participated as a sequencing service provider in phase I study (SG10k), and have collaborated with Illumina to sequence and analyze 100,000 Singaporean whole genomes as part of NPM Phase II study (SG100K). In addition, we are proud to announce our appointment as the sequencing service provider for sequencing 10,000 genomes using Oxford Nanopore technology under the NPM program’s Phase II.

“The National Precision Medicine (NPM) Project is a landmark initiative to transform healthcare by leveraging advancements in genomics,” said Justin Lee, CEO of NovogeneAIT. “We are proud to carry out the sequencing for this project and contribute to one of the most extensive and inclusive reference genome datasets in the world. This collaboration not only underscores our commitment to precision healthcare but also positions Singapore as a key genomics hub in the Asia Pacific region.”

NovogeneAIT Genomics boasts a state-of-the-art laboratory facilitiy and extensive expertise in next-generation sequencing, ensuring high-standard and reliable data. To better support the NPM program, NovogeneAIT Genomics has been equipped with advanced sequencing platforms, lab automations, and IT infrastructure to ensure robust and high quality results.

At NovogeneAIT Genomics, we are dedicated to the success of this project and contributing to the healthcare ecosystem of Singapore. We look forward to the advancements in medical research and precision medicine that will emerge from this collaboration.

About NovogeneAIT Genomics

NovogeneAIT Genomics is a leading multi-omics services and solutions provider headquartered in Singapore. It is formed as a strategic joint venture between Novogene and AITbiotech, a Singapore biotech Company in 2016. With an unwavering commitment to delivering high-quality, swift, and cost-effective omics solutions, NovogeneAIT Genomics has grown to become one of the largest NGS service providers in Southeast Asia. It offers a comprehensive suite of multi-omics services encompasses genomics, transcriptomics, single cell/spatial transcriptomics, metagenomics, and proteomics. Operating from our state-of-the-art sequencing center in Singapore, NovogeneAIT is dedicated to advancing genomic research by offering unmatched data quality that empowers researchers across diverse sectors, including healthcare and agriculture, to realize their research goals. For more information, visit http://www.novogene.com/amea-en/

About Novogene

Novogene is a pioneer in applying cutting-edge molecular biology technology and high-performance computing to research in the fields of life science and human health. Our vision is to continue as a global leader in the delivery of genomics services and solutions. With one of the largest sequencing capacities in the world, we utilise our deep scientific knowledge, first-class customer service and unsurpassed data quality to help clients realise their research goals in the rapidly evolving world of genomics. Novogene is committed to become your trusted genomics partner.